MIR429 (MicroRNA 429)

News alerts, weekly reports and conference planners

Entrez ID:

miR-429 underexpression	Non Small Cell Lung Cancer	miR-429 underexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
miR-429 underexpression	Non Small Cell Lung Cancer	miR-429 underexpression	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
miR-429 expression	Pancreatic Cancer	miR-429 expression	Pancreatic Cancer	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D

Associations(3)